openPR Logo
Press release

Severe Rheumatoid Arthritis Treatment available at Axium Healthcare Pharmacy

02-05-2010 11:06 AM CET | Health & Medicine

Press release from: Axium Healthcare Pharmacy

Axium Healthcare Pharmacy

Axium Healthcare Pharmacy

Lake Mary, Fla. (February 4, 2010) – Axium Healthcare Pharmacy, one of the nation’s largest independent specialty pharmacy providers, has been granted access to provide Actemra® (tocilizumab) for the treatment of adult patients with moderate to severe rheumatoid arthritis (RA).

The announcement comes on the heels of the FDA’s approval of Genentech’s Actemra® (tocilizumab). Actemra® is indicated for adult RA patients who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Actemra® is approved for once-a-month intravenous administration in settings such as doctor’s offices, hospitals and infusion centers. Actemra® may be used alone or in combination with methotrexate or other disease modifying anti-rheumatic drugs (DMARDs).

“Axium is pleased to be granted the opportunity to provide Actemra® for severe rheumatoid arthritis,” stated Mark Montgomery, President & CEO of Axium Healthcare Pharmacy. “We remain committed in expanding our product offerings to service a wider array of patients. Through Axium’s therapy management program, we are able to deliver high-quality, patient-focused care and personalized superior service combined with our dedicated clinical expertise which further brings a new level of care for our patients.”

Axium’s clinical team provides comprehensive compliance support, patient education and other clinical interventions and communication with the patient/physician to coordinate the treatment plan. In addition, Axium offers 24-hour Pharmacist/Nurse support, prior authorization assistance, refill management calls, and ongoing delivery coordination.

About Axium Healthcare Pharmacy:

Axium Healthcare Pharmacy, Inc. is one of the nation’s largest independent specialty pharmacy providers licensed and permitted to operate in all 50 states and Puerto Rico. Axium focuses on therapy management programs for patients with serious and chronic conditions. Therapy management programs include: Hepatitis C, Oncology, Multiple Sclerosis, Rheumatoid Arthritis, Hemophilia, Growth Hormone Deficiency plus others. For more information, contact Axium Healthcare Pharmacy at 888.315.3395; by email info (at) axiumhealthcare (dot) com or visit us at http://www.axiumhealthcare.com

Axium Healthcare Pharmacy
550 Technology Park
Lake Mary, FL 32746

Axium Healthcare Pharmacy
prcontact@vayumedia.com
888-315-3395

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Severe Rheumatoid Arthritis Treatment available at Axium Healthcare Pharmacy here

News-ID: 119823 • Views:

More Releases from Axium Healthcare Pharmacy

Indonesia: Health care mega-spending –whose have no complaints?
AXIS Capital is a group of global insurer and reinsurer, providing clients and distribution partners with a broad range of specialized risk transfer products and services, i.e. health insurance that serves a host of industries and diverse coverage needs through our operating subsidiaries and branch offices in Bermuda, Australia, Canada, Europe, Latin America, Singapore and the United States. Indonesia is obligating billions of dollars as it targets to meet the government’s
Axium Healthcare Pharmacy Adds New Hepatitis C Drugs to their HEPVisionsSM Thera …
Axium Healthcare Pharmacy, one of the nation’s largest independent specialty pharmacy providers, announced today the addition of VictrelisTM and IncivekTM to its HEPVisionsSM Therapy Management Program. The announcement comes on the heels of the FDA’s approval of Merck’s VictrelisTM and Vertex’s IncivekTM. Both drugs are approved for use in combination with peg interferon and ribavirin, creating a triple therapy regimen. Clinical trials have shown that using one of the
Axium Healthcare Pharmacy Receives 2011 SMART Awards Recognition
Axium Healthcare Pharmacy Receives 2011 SMART Awards Recognition
Axium Healthcare Pharmacy, one of the nation’s largest independent specialty pharmacy providers, announced today that it has been selected as the 2011 SMART Awards recipient in the Healthcare & Life Sciences category by the Orlando Chapter of the Association for Corporate Growth (ACG Orlando). “We’re proud to be recognized as a recipient of the 2011 SMART Awards,” said Mark Montgomery, President and CEO of Axium Healthcare Pharmacy. “It is through
Axium Healthcare Puerto Rico Selects Borschow Hospital & Medical Supplies, Inc. …
Lake Mary, Fla. (June 15, 2010) – Axium Healthcare Pharmacy, one of the nation’s largest independent specialty pharmacy providers, announced today that its subsidiary, Axium Healthcare Puerto Rico, has selected Borschow Hospital & Medical Supplies, Inc. as the primary wholesale distributor in Puerto Rico. “This strategic business relationship with Borschow strengthens our specialty biotech purchase platform for growth in Puerto Rico,” stated Milton Latoni, General Manager of Axium Healthcare

All 5 Releases


More Releases for Actemra®

Actemra Market Evolving Rapidly Through 2025 to 2032 | Genentech (Part of Roche) …
Actemra The latest Actemra Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2025 and 2032. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The Industry compass guiding business through the complexities of the market, presenting not only the current landscape but also the latest innovations shaping its future.
Actemra Market Survey Detailed Analysis and Forecast 2025-2032 | Genentech (Part …
The latest Actemra Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2025 and 2032. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The Industry compass guiding business through the complexities of the market, presenting not only the current landscape but also the latest innovations shaping its future. This
Actemra (Tocilizumab) Market Report 2025-2034: Industry Overview, Trends, And Fo …
The Actemra (Tocilizumab) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Actemra (Tocilizumab) Market Size and Projected Growth Rate? In recent years, the Actemra (tocilizumab) market has experienced swift expansion. Projected growth sees it increasing from $5,160 million in 2024 to $5,710 million
Key Trend Reshaping the Actemra (Tocilizumab) Market in 2025: Emergence Of Biosi …
What market dynamics are playing a key role in accelerating the growth of the actemra (tocilizumab) market? The growing incidence of rheumatoid arthritis, a chronic autoimmune disease that results in joint inflammation, impairment, and a lowered quality of life, is set to stimulate the development of the actemra (tocilizumab) market. Influenced by factors such as smoking, obesity, environmental exposure, and hormonal factors, rheumatoid arthritis affects millions worldwide. Actemra (tocilizumab) serves to
Actemra (Tocilizumab) Market Outlook 2025-2034: Key Trends, Growth Drivers, and …
What Are the Market Size and Growth Forecast for the Actemra (Tocilizumab) Market? In recent times, the actemra (tocilizumab) market has expanded swiftly. It is projected to escalate from $5,160 million in 2024 to $5,710 million in 2025, realizing a compound annual growth rate (CAGR) of 10.7%. Growth in the historic phase is linked to the escalating incidence of autoimmune diseases, accelerated adoption of biologic treatments, increased consciousness about chronic inflammatory
Actemra (Tocilizumab) Market Outlook 2025-2034: Key Trends, Growth Drivers, and …
What Are the Market Size and Growth Forecast for the Actemra (Tocilizumab) Market? In recent times, the actemra (tocilizumab) market has expanded swiftly. It is projected to escalate from $5,160 million in 2024 to $5,710 million in 2025, realizing a compound annual growth rate (CAGR) of 10.7%. Growth in the historic phase is linked to the escalating incidence of autoimmune diseases, accelerated adoption of biologic treatments, increased consciousness about chronic inflammatory